Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of March 2022

 

 

 

Commission File Number: 001-39487

 

 

 

Silence Therapeutics plc

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

72 Hammersmith Road

London W14 8TH

United Kingdom

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒           Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

---

 

Filed as Exhibit 99.1 to this Report on Form 6-K is a press release of Silence Therapeutics plc, dated March 23, 2022.

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press release, dated March 23, 2022, “Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501”.

 

---

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Silence Therapeutics plc
	By:	/s/ Craig Tooman
		Name:	Craig Tooman
		Title:	President and Chief Executive Officer

 

Date: March 23, 2022